trial · primary record
Ammoxetine
Major Depressive Disorder (MDD)
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 786 |
| Primary completion | 2026-08-20 |
| Primary endpoint | Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8) |
| Registry ID | NCT06827431 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:05.037Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06827431
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.